Zentalis Pharmaceuticals (NASDAQ:ZNTL) Raised to “Sell” at Wall Street Zen

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also issued reports on ZNTL. Mizuho began coverage on shares of Zentalis Pharmaceuticals in a report on Friday, July 17th. They issued an “outperform” rating and a $8.00 price objective for the company. Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 target price for the company. Jefferies Financial Group raised Zentalis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 14th. William Blair began coverage on Zentalis Pharmaceuticals in a research report on Wednesday, September 16th. They issued an “outperform” rating on the stock. Finally, Wedbush upgraded Zentalis Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $5.00 to $6.00 in a research note on Tuesday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.29.

View Our Latest Analysis on Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $1.70 on Friday. Zentalis Pharmaceuticals has a fifty-two week low of $1.28 and a fifty-two week high of $6.95. The stock’s fifty day moving average is $2.53 and its two-hundred day moving average is $3.38. The firm has a market capitalization of $121.84 million, a P/E ratio of -0.89 and a beta of 1.91.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.20. On average, equities analysts forecast that Zentalis Pharmaceuticals will post -1.80 earnings per share for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. 5AM Venture Management LLC purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth about $19,147,378. BlackRock Inc. acquired a new position in shares of Zentalis Pharmaceuticals during the second quarter worth about $18,205,000. Bank of America Corp DE acquired a new position in shares of Zentalis Pharmaceuticals during the second quarter worth about $5,406,000. Primecap Management Co. CA acquired a new position in shares of Zentalis Pharmaceuticals during the second quarter worth about $4,643,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth approximately $3,676,000.

Key Stories Impacting Zentalis Pharmaceuticals

Here are a few of the latest stories about ZNTL:

  • Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $10 price target while substantially narrowing its projected losses for 2026–2028. For example, its FY2027 EPS forecast improved to ($1.90) from ($2.76), and its FY2028 estimate improved to ($1.64) from ($2.13). The repeated reports describe the same broad estimate revisions, rather than separate analyst actions.
  • Positive Sentiment: Wedbush upgraded Zentalis’s stock rating, another potentially supportive analyst signal. Zentalis Pharmaceuticals Stock Rating Upgraded by Wedbush
  • Negative Sentiment: HC Wainwright lowered its FY2029 and FY2030 EPS forecasts, to ($1.10) from ($1.00) and to ($0.42) from ($0.18), respectively. These later-year cuts partially offset its more favorable revisions for nearer-term years.

About Zentalis Pharmaceuticals

(Get Free Report)

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer. Its research centers on therapies that target biological processes involved in tumor growth. The company’s lead drug candidate, azenosertib (formerly known as ZN-c3), is an investigational inhibitor of WEE1, a protein involved in cell-cycle regulation. It has been studied in clinical trials for ovarian cancer and other solid tumors. Zentalis has also advanced other oncology drug candidates, including compounds targeting cancer-related proteins.

Featured Articles

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.